How to buy Aeglea BioTherapeutics (AGLE) stock

Aeglea BioTherapeutics, Inc is a biotechnology business based in the US. Aeglea BioTherapeutics shares (AGLE) are listed on the NASDAQ and all prices are listed in US Dollars. Aeglea BioTherapeutics employs 88 staff and has a market cap (total outstanding shares value) of 0.00.

Aeglea BioTherapeutics stock price (NASDAQ: AGLE)

Use our graph to track the performance of AGLE stocks over time.

Aeglea BioTherapeutics shares at a glance

• Key figures

Information last updated 2021-07-22.

Latest market close	$6.61
52-week range	$6.15 - $9.90
50-day moving average	$6.85
200-day moving average	$7.42
Wall St. target price	$15.86
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.30

Buy Aeglea BioTherapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Aeglea BioTherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Aeglea BioTherapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aeglea BioTherapeutics price performance over time

Historical closes compared with the close of $6.61 from 2021-05-28

1 week (2021-07-17)	N/A
1 month (2021-06-28)	-10.92%
3 months (2021-04-28)	-19.09%
6 months (2021-01-24)	N/A

1 year (2020-07-24)	N/A
2 years (2019-07-24)	N/A
3 years (2018-07-24)	N/A
5 years (2016-07-24)	N/A

Aeglea BioTherapeutics financials

Gross profit TTM	$-59,638,000
Return on assets TTM	-44.15%
Return on equity TTM	-96.52%
Profit margin	0%
Book value	$2.53
Market capitalisation	$323.6 million

TTM: trailing 12 months

Shorting Aeglea BioTherapeutics shares

There are currently 2.0 million Aeglea BioTherapeutics shares held short by investors – that's known as Aeglea BioTherapeutics's "short interest". This figure is 7.6% down from 2.2 million last month.

There are a few different ways that this level of interest in shorting Aeglea BioTherapeutics shares can be evaluated.

Aeglea BioTherapeutics's "short interest ratio" (SIR)

Aeglea BioTherapeutics's "short interest ratio" (SIR) is the quantity of Aeglea BioTherapeutics shares currently shorted divided by the average quantity of Aeglea BioTherapeutics shares traded daily (recently around 278541.23287671). Aeglea BioTherapeutics's SIR currently stands at 7.3. In other words for every 100,000 Aeglea BioTherapeutics shares traded daily on the market, roughly 7300 shares are currently held short.

However Aeglea BioTherapeutics's short interest can also be evaluated against the total number of Aeglea BioTherapeutics shares, or, against the total number of tradable Aeglea BioTherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aeglea BioTherapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Aeglea BioTherapeutics shares in existence, roughly 40 shares are currently held short) or 0.0621% of the tradable shares (for every 100,000 tradable Aeglea BioTherapeutics shares, roughly 62 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Aeglea BioTherapeutics.

Find out more about how you can short Aeglea BioTherapeutics stock.

Aeglea BioTherapeutics share dividends

We're not expecting Aeglea BioTherapeutics to pay a dividend over the next 12 months.

Aeglea BioTherapeutics share price volatility

Over the last 12 months, Aeglea BioTherapeutics's shares have ranged in value from as little as $6.15 up to $9.9. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeglea BioTherapeutics's is 1.6251. This would suggest that Aeglea BioTherapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Aeglea BioTherapeutics overview

Aeglea BioTherapeutics, Inc. , a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes cystinuria and research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015.

Frequently asked questions

What percentage of Aeglea BioTherapeutics is owned by insiders or institutions?
Currently 2.526% of Aeglea BioTherapeutics shares are held by insiders and 92.856% by institutions. How many people work for Aeglea BioTherapeutics?
Latest data suggests 88 work at Aeglea BioTherapeutics. When does the fiscal year end for Aeglea BioTherapeutics?
Aeglea BioTherapeutics's fiscal year ends in December. Where is Aeglea BioTherapeutics based?
Aeglea BioTherapeutics's address is: 805 Las Cimas Parkway, Austin, TX, United States, 78746 What is Aeglea BioTherapeutics's ISIN number?
Aeglea BioTherapeutics's international securities identification number is: US00773J1034 What is Aeglea BioTherapeutics's CUSIP number?
Aeglea BioTherapeutics's Committee on Uniform Securities Identification Procedures number is: 00773J103